Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up

Authors

Zachary Abramson, Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, United States.Follow
Orrin L. Dayton, Departments of Radiology, University of Florida College of Medicine, Gainesville, FL, United States.
Walter E. Drane, Departments of Radiology, University of Florida College of Medicine, Gainesville, FL, United States.
William M. Mendenhall, Departments of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, United States.
Frederic J. Kaye, Departments of Medicine, University of Florida College of Medicine, Gainesville, FL, United States. Electronic address: fkaye@ufl.edu.

Abstract

We present 8-year follow-up on the first patient with stage 4 ameloblastoma carrying a BRAF V600E mutation treated with dual BRAF/MEK inhibition (BRAF/MEKi). He experienced a durable clinical response while on dabrafenib (BRAFi) and trametinib (MEKi) without toxicity nor evidence for drug-resistant tumor progression. He was asymptomatic when he self-discontinued therapy after 4 years of sustained clinical response. He did not return for follow-up until 2.5 years later with onset of painful mandibular tumor recurrence associated with recurrent bilateral lung metastases. He was rechallenged with dabrafenib/trametinib and experienced another prompt tumor response and remains in a second durable clinical remission (currently > 16 months) on continuous dual targeted therapy. We discuss the implications of this case study for future treatment strategies.

Publication Title

Oral oncology

Recommended Citation

Abramson, Zachary; Dayton, Orrin L.; Drane, Walter E.; Mendenhall, William M.; and Kaye, Frederic J., "Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up" (2022). Loewenberg College of Nursing Faculty Publications. 99.
https://digitalcommons.memphis.edu/lcon-facpubs/99